Reuters logo
BRIEF-Editas receives EMA's orphan medicinal product designation for EDIT-101
2017年9月26日 / 晚上8点22分 / 21 天前

BRIEF-Editas receives EMA's orphan medicinal product designation for EDIT-101

Sept 26 (Reuters) - Editas Medicine Inc

* Editas Medicine receives EMA’s orphan medicinal product designation for EDIT-101 for the treatment of LCA10

* Editas Medicine plans to submit an investigational new drug (IND) application for EDIT-101 in mid-2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below